Annals of Epidemiology
Volume 16, Issue 2 , Pages 85-90, February 2006

Cardiovascular Risk Among Men Seeking Help for Erectile Dysfunction

From Radboud University Medical Centre, Nijmegen, the Netherlands (J.F., T.G.W.S., L.A.K., E.J.H.M.)

Received 3 December 2004; accepted 20 June 2005. published online 13 October 2005.

Purpose

The introduction of sildenafil put the risk of cardiovascular disease (CVD) among men with erectile dysfunction (ED) on the agenda of physicians. The question arose, Is EDsentinel to CVD? We sought to answer this question in the present study.

Methods

A historical cohort study was set up using medical records of general practices all over the Netherlands. Incident cases of ED were selected before and after the introduction of sildenafil using a catchment population of 60,000 men aged 35 to 74 years. Two to three men without ED (controls) were, subsequently, matched to each case. Incidence of CVD was determined for cases and controls, respectively.

Results

Overall, incidence of ED doubled from 5.3 per 1000 men-years in the period before introduction of sildenafil to 10.1 after the introduction. The relative risk of incident CVD among men with ED compared to controls was 1.7 [95%-CI 0.9–3.3] before the introduction and 1.1 [95%-CI 0.6–1.8] afterwards.

Conclusions

While ED could be seen as a marker for CVD before the introduction of sildenafil, it was clearly not afterwards.

Key words: Erectile Dysfunction, Cardiovascular Disease, Sildenafil, Prevention

Selected Abbreviations: ED, erectile dysfunction, CVD, cardiovascular disease, CI, confidence interval (95%)

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported by an unrestricted grant from Pfizer International, New York.

PII: S1047-2797(05)00241-3

doi:10.1016/j.annepidem.2005.06.047

Annals of Epidemiology
Volume 16, Issue 2 , Pages 85-90, February 2006